Pharmaceutical

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer

Dr. Quezada-Ruiz, an internationally recognized ophthalmologist and experienced drug development leader, has joined the company as Chief Medical Officer.Seemi Khan,...

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old...

Tata Elxsi, University of Illinois Urbana-Champaign, and OSF HealthCare Partner to Transform Rural Healthcare Access in the United States

Collaboration Leverages Digital Kiosks and AI-Driven Platforms to Bridge Healthcare GapsBENGALURU, India and CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Tata...

ZAGENO Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership

ZAGENO earns global recognition for driving innovation, operational efficiency, and transformative customer value across the life sciences e-commerce ecosystem.SAN ANTONIO,...

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly...

The Frost & Sullivan Institute Honors Global Organizations Pioneering Responsible Growth With the 2025 Visionary Growth Leadership Best Practices Recognition

SANTA CLARA, Calif., Dec. 1, 2025 /PRNewswire/ -- The Frost & Sullivan Institute is proud to announce the recipients of...

error: Content is protected !!